🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I am thrilled to share that the first preprint from my lab is now available on bioRxiV! In this study, our team elucidates the role of autocrine ligands in the aberrant behavior of oncogene-driven lung cancer. biorxiv.org/content/10.110…

🚨 New Study on SBRT vs. Conventional RT for Painful Bone Metastases! 🚨OncoAlert 🎯 Study Objective Compare the effectiveness of dose-escalated SBRT (20 Gy) vs. conventional RT (8 Gy) in achieving complete pain response for painful bone metastases 🏥 Methods • Design: Phase

Congrats to our #MedPhys graduates! 🎓🎉 Shown with Program Director, Dr. Michael Altman are Haleem Azmy (MSMP), Sean Fan (MSMP), & (Front row) Dr. Zhihua Liu (Post PhD Certificate in Medical Physics) & Sarah Cradick (MSMP). #WashU25

Article here: jitc.bmj.com/content/13/5/e… Clinically, ATM mutations are the third most common DDR defect (breast, prostate, lung, pancreas). DNA repair can defects increase immunogenicity by increasing neo-antigens or activating cGAS/STING. Many assumed ATM tumors may be similar.

Congrats to WashU Medicine Radiation Oncology PGY4 resident Dan Hong for completing his Master of Science in Clinical Investigation (MSCI)! So proud!! @WashUMedicine #WashU2025 #trainherethriveanywhere

Great job Dr. Hong! #WashU25

Radiation-induced amphiregulin drives tumor metastasis nature Ralph Weichselbaum Andras Piffko Sean Pitroda, M.D. nature.com/articles/s4158…

To all of you radiation scientists planning to apply for the NIH PAIRS funding mechanism (PAR-22-198) for June 5, I just learned that it was cancelled (though the website states it is active). Bad news, but I guess now I can go drink margaritas 🍹

3 MD/PhDs, 3 future radiation oncologists, 3 future physician scientists, and I just couldn't' be prouder ❤️❤️❤️

Temporal and context-dependent requirements for Foxp3 expression in Treg researchsquare.com/article/rs-659…

Excited to share our study describing a role for a subset of Thetis cells, TC IV, in tolerance to food antigens. A team effort led by Vanja Cabric and Yollanda Parisotto 🧵 1/ science.org/doi/10.1126/sc…

Nature research paper: Clonal tracing with somatic epimutations reveals dynamics of blood ageing go.nature.com/44NkN1P

#3/n However Transcriptomes were markedly distinct with ECM genes high in A vs Immune genes activation in D types. This was corroborated by deconvolution analyses and GSVA

Cemiplimab seems to be very good at “salvaging” recurrences. So it begs the question whether we should expose all patients to the drug when the majority will never need it at all. It is critical to asses QoL at recurrence (and afterwards) to understand what’s happening in

Very powerful and insightful discussion by Prof Kevin Harrington The Royal Marsden Cancer Charity on KN-630 and C-POST The slides speak volumes and it isn’t just about the timing of anti-PD-1 😜 Sana Karam, MD, PhD C. Jillian Tsai, MD, PhD Sean McBride Pierre Blanchard, MD #ASCO2025 #Skincancer #Cutaneouscancer

#ASCO2025 #HeadNeckCancer #NasopharyngealCarcinoma This is going to be provocative Toripalimab and concurrent RT, replacing CDDP in LA-NPC showing equipoise Any comments on this approach? Sana Karam, MD, PhD 😜

An atlas of transcription factor-driven gene programs across human cells Teichlab biorxiv.org/content/10.110…

💡Seminal international 🇺🇸🇨🇦 efforts evaluating proactive vs reactive swallowing therapy during HNRT. - No meaningful difference b/w 3 arms ➡️ allows choice based on patient/clinic factors. Congrats Kate Hutcheson Rosemary Martino Neil Woody Princess Margaret Cancer Centre

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

Delighted to present path response from our Neoadjuvant ImmunoRadioTherapy (NIRT-2) trial in pts w HPV- HNSCC ASCO mPR=71% pCR=29% Downstaging=67% Omission of adjuvant RT=83% Surgical de-escalation=50% Earle A. Chiles Research Institute UCSD Health Moores Cancer Center COE Joseph Califano UCSD Cancer #ASCO25 meetings.asco.org/abstracts-pres…